Who
Alane P. Barnes
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, BioCryst Pharmaceuticals.
In numbers
- Trades disclosed
- 109
- Buys
- 2
- Sells
- 15
- Bought
- $57K
- Sold
- $7.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Jan 2014
- Last trade
- 13 May 2026
- Last filed
- 15 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 May 2026filed 15 May 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $315K62,500 at $5.04 | filing |
| 13 May 2026filed 15 May 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $596K62,500 at $9.54 | filing |
| 13 May 2026filed 15 May 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —62,500 at $0.00 | filing |
| 13 May 2026filed 15 May 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —62,500 at $0.00 | filing |
| 13 May 2026filed 15 May 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $315K62,500 at $5.04 | filing |
| 13 May 2026filed 15 May 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $596K62,500 at $9.54 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $827K150,000 at $5.51 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.4M150,000 at $9.15 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —150,000 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —150,000 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $827K150,000 at $5.51 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.4M150,000 at $9.15 | filing |
| 22 Dec 2025filed 23 Dec 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $167K21,773 at $7.65 | filing |
| 19 Dec 2025filed 23 Dec 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $125K16,902 at $7.41 | filing |
| 17 Dec 2025filed 19 Dec 2025 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —255,050 at $0.00 | filing |
| 17 Dec 2025filed 19 Dec 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —121,700 at $0.00 | filing |
| 15 Dec 2025filed 16 Dec 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $162K21,210 at $7.65 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $65K8,540 at $7.57 | filing |
| 3 Dec 2025filed 3 Dec 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $151K19,770 at $7.65 | filing |
| 2 Dec 2025filed 3 Dec 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $367K50,906 at $7.21 | filing |
News
No headline names them, or the companies they trade most, lately.